Literature DB >> 14758570

Concentration of insulin-like growth factor (IGF)-I in iliac crest bone matrix in premenopausal women with idiopathic osteoporosis.

C E Pepene1, T Seck, I Diel, H W Minne, R Ziegler, J Pfeilschifter.   

Abstract

Previous studies have shown a link between low serum insulin-like growth factor-I (IGF-I) and decreased bone mass of patients with osteoporosis. However, whether serum levels are representative for the growth factor concentration or activity available in human bone tissue is controversial. In the present study, IGF-I was assessed in serum and bone matrix extracts from the iliac crest in 19 eugonadal women with idiopathic osteoporosis and in 38 age-matched controls. In addition, the relationship between the skeletal levels of IGF-I and bone mineral density (BMD) or the susceptibility to osteoporotic fractures in women with osteoporosis was examined. Bone matrix extraction was performed based on a guanidine-HCL/ethylendiamine-tetraacetic acid (EDTA) method. No significant difference in both serum and bone matrix IGF-I levels between groups was observed. Serum IGF-I concentrations failed to be associated with bone matrix IGF-I levels in osteoporotic patients. However, in premenopausal women with idiopathic osteoporosis, skeletal IGF-I positively correlated with BMD at the lumbar spine (r = + 0.58, p = 0.01). In contrast, neither femoral neck BMD nor Ward's triangle BMD was associated with bone matrix IGF-I concentrations. A tendency towards lower levels of bone matrix IGF-I in subjects with vertebral fractures as compared to those without fractures was observed in age-adjusted analyses, however the difference failed to remain statistically significant after adjustment for bone mineral density. These data provide no clear evidence for low bone matrix IGF-I as a determinant factor of age-unrelated osteoporosis. However, low skeletal IGF-I concentrations may aggravate osteoporosis in these women.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14758570     DOI: 10.1055/s-2004-815725

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  5 in total

1.  Quantification of growth factors in allogenic bone grafts extracted with three different methods.

Authors:  B Wildemann; A Kadow-Romacker; A Pruss; N P Haas; G Schmidmaier
Journal:  Cell Tissue Bank       Date:  2006-10-25       Impact factor: 1.522

2.  ASSOCIATION OF COL1A1 SP1 AND FOK-I VDR GENETIC POLYMORPHISMS IN YOUNG MALE IDIOPATHIC OSTEOPOROSIS.

Authors:  S C Man; M Chiriac; M S Militaru; A P Trifa; M Goia-Socol; C E Georgescu
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Apr-Jun       Impact factor: 0.877

3.  [Study on the correlation between the content of bone morphogenetic protein 2 in demineralized bone matrix and its osteogenic activity in vitro and in vivo].

Authors:  Miao Li; Yulong Bai; Xiaoliang Pan; Jingjing Wang; Weiming Chen; Jingwan Luo; Kai Hu; Jinfa Chen
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-05-15

4.  Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis.

Authors:  Seunghyun Lee; Namki Hong; Kyoung Jin Kim; Chung Hyun Park; Jooyeon Lee; Yumie Rhee
Journal:  Calcif Tissue Int       Date:  2021-05-26       Impact factor: 4.333

5.  Cancellous bone properties and matrix content of TGF-beta2 and IGF-I in human tibia: a pilot study.

Authors:  Yener N Yeni; X Neil Dong; Bingbing Zhang; Gary J Gibson; David P Fyhrie
Journal:  Clin Orthop Relat Res       Date:  2009-05-27       Impact factor: 4.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.